Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
The addition of Celgene made Bristol’s sales team pharma’s most productive last year on one measure, but the accolade might be short-lived.
A small molecule for alpha-1 antitrypsin deficiency faces a key clinical test, and its chances of success aren’t good.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
The company’s lead cystic fibrosis asset fails, shifting the focus to the Sanofi-partnered Covid-19 vaccine.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.